Highlight 1: pancreatic and biliary cancer
Dr Willem Lybaert, a medical oncologist at VITAZ Sint-Niklaas and UZ Antwerp, brings us the daily highlights on pancreatic and biliary cancer. He delves into four notable studies, two of which focus on pancreatic cancer.
The first study, known as the NAPOLI 3 STUDY, compares the efficacy of NALIRIFOX versus the combination of gemcitabine and nab-paclitaxel as a first-line treatment for pancreatic cancer.
The second study discussed is the TIGeR-PaC study, which introduces intra-arterial gemcitabine as a potential treatment option for pancreatic cancer.
Moving on to biliary tract cancer, Dr Lybaert presents two studies of interest. The NuTide study evaluates NUC-1031, an improved formulation of gemcitabine, in comparison to standard treatment.
Lastly, Dr Lybaert addresses the numerous new findings in the second and subsequent lines of treatment for biliary tract cancer, emphasizing the complexities of navigating this landscape of emerging molecular targeted therapies.
With the educational support of:
